Dacopafant is platlet activationg factor receptor (PAFR) antagonists. It had been in phase I clinical trials by Sanofi for the treatment of systemic inflammatory response syndrome and asthma. However, this research has been discontinued. References: Serradji N, Bensaid O, Martin M, Kan E, Dereuddre-Bosquet N, Redeuilh C, Huet J, Heymans F, Lamouri A, Clayette P, Dong CZ, Dormont D, Godfroid JJ. Structure-activity relationships in platelet-activating factor (PAF). 10. From PAF antagonism to inhibition of HIV-1 replication. J Med Chem. 2000 Jun 1;43(11):2149-54. PubMed PMID: 10841793.

纯度：≥98%

CAS：125372-33-0